Clinical Trials Directory

Trials / Unknown

UnknownNCT00591292

Phase I Study in Advanced Solid Tumors

IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
22 (actual)
Sponsor
Alaunos Therapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGindibulinDose escalation of indibulin given twice daily for up to 6 months

Timeline

Start date
2007-06-01
Primary completion
2013-06-01
Completion
2013-06-01
First posted
2008-01-11
Last updated
2012-07-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00591292. Inclusion in this directory is not an endorsement.

Phase I Study in Advanced Solid Tumors (NCT00591292) · Clinical Trials Directory